

REMARKS

Claims 37-65 are pending in the present application.

The Examiner has required election in the present application between:

Group I, claims 37-40, 44 and 56, drawn to compounds and compositions reading on n is 2, X is O, A is benzimidazole drawn to azabicycl[2.2.2]octane-benzimidazole-ethers;

Group II, claims 37-40, 47, 48 and 56, drawn to compounds and compositions reading on n is 2, X is O, -CH₂-O, or -CH₂-CH₂-, A is isoindole-1,3-dione drawn to azabicycl[2.2.2]octane-isoindole-1,3-diones; and

Group III, claims 37-40, 44, 45, 46 and 56, drawn to compounds and compositions reading on n is 2, X is O, A is pyridazine drawn to azabicycl[2.2.2]octane-pyridazine-ethers; and

Group IV, claims 37-43 and 56, drawn to compounds and compositions reading on n is 2, X is O, A is phenyl, indenyl, naphthyl or tetrahydronaphthyl, drawn to azabicycl[2.2.2]octane-(phenyl/tetrahydronaphthyl/naphthyl/indenyl)-ethers; and

Group V, claims 37-40, 44, 45, 46 and 56, drawn to compounds and compositions reading on n is 2, X is O, A is 1,2,4-thiadiazole, drawn to azabicycl[2.2.2]octane-1,2,4-thiadiazole-ethers; and

Group VI, claims 37-40, 44, 45, 46 and 56, drawn to compounds and compositions reading on n is 2, X is O, A is thiazole, drawn to azabicycl[2.2.2]octane-thiazole-ethers; and

Group VII, claims 37-40, 44, 47, 48 and 56, drawn to compounds and compositions reading on n is 2, X is O, A is quinoline, drawn to azabicycl[2.2.2]octane-quinoline-ethers; and

Group VIII, claims 37-40, 44, 47, 48 and 56, drawn to compounds and compositions reading on n is 2, X is O, A is quinoxaline, drawn to azabicycl[2.2.2]octane-quinoxaline-ethers; and

Group IX, claims 37-40, 47, 55 and 56, drawn to compounds and compositions reading on n is 2, X is O, A is imidazo[1,2-b]pyridazine, drawn to azabicycl[2.2.2]octane-imidazo[1,2-b]pyridazine-ethers; and

Group X, claims 37-40, 44, 47, 48 and 56, drawn to compounds and compositions reading on n is 2, X is O, A is benzothiazole or benzoisothiazole, drawn to azabicycl[2.2.2]octane-(benzothiazole/benzoisothiazole)-ethers; and

Group XI, claims 37-40, 47, 48 and 56, drawn to compounds and compositions reading on n is 2, X is O, A is benzothiazole or benzoisothiazole, drawn to azabicycl[2.2.2]octane-benzotriazole-ethers; and

Group XII, claims 37-40, 44, 45, 46 and 56, drawn to compounds and compositions reading on n is 2, X is O, A is thiophene, drawn to azabicycl[2.2.2]octane-thiophene-ethers; and

Group XIII, claims 37-40, 44, 47, 48 and 56, drawn to compounds and compositions reading on n is 2, X is O, A is benzoxazole, drawn to azabicycl[2.2.2]octane-benzoxazole-ethers; and

Group XIV, claims 37-40, 47 and 56, drawn to compounds and compositions reading on n is 2, X is O, A is dibenzofuran, drawn to azabicycl[2.2.2]octane-dibenzofuran-ethers; and

Group XV, claims 37-40, 44-45, 47, 49-54 and 56, drawn to remaining compounds not delineated in any of the above groups drawn to for example compounds and compositions reading on n is 2, X is O, A is pyrrolo[1,2-b]pyridazine, drawn to azabicycl[2.2.2]octane-pyrrolo[1,2-b]pyridazine-ethers; and

Group XVI, claims 57-59, drawn to methods of treating central nervous system disorders, limited in scope to one of the compounds of Groups I-XV; and

Group XVII, claims 57, 60, drawn to methods of treating diseases disorders, etc. associated with "smooth muscle contractions", limited in scope to one of the compounds of Groups I-XV, and

Group XVIII, claims 57, 61, drawn to methods of treating disease disorders etc. associated with the endocrine system, limited in scope to one of the compounds of Groups I-XV; and

Group XIX, claims 57, 62, drawn to methods of treating neurodegenerative disorders, limited in scope to one of the compounds of Groups I-XV; and

Group XX, claims 57, 63, drawn to methods of treating inflammatory disorders, limited in scope to one of the compounds of Groups I-XV; and

Group XXI, claims 57, 64, drawn to methods of treating pain, limited in scope to one of the compounds of Groups I-XV; and

Group XXII, claims 57, 65 drawn to methods of treating diseases associated with withdrawal, limited in scope to one of the compounds of Groups I-XV

For the purpose of examination of the present application, Applicants elect, without traverse, Group III, Claims 37-40, 44, 45 46 and 56 drawn to compounds and compositions reading on n is 2, X is O, A is pyridazine drawn to azabicycl[2.2.2]octane-pyridazine-ethers.

The Examiner has required an election in the present application between:

For the purpose of examination of the present application, Applicants elect Species listed in claim 46, i.e., (\pm)-3-[6-Thienyl]-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane as a single species, without traverse.

Claim 46 is directed to the elected species. At least elected claims 37-40, 44, 45 and 56 are generic.

Should there be any outstanding matters that need to be resolved in the present application, the Examiner is respectfully requested to contact MaryAnne Armstrong, Ph.D., Registration No 40,069 at the telephone number of the undersigned below, to conduct an interview in an effort to expedite prosecution in connection with the present application.

- ☐ Attached is a Petition for Extension of Time.
- ☐ Attached hereto is the fee transmittal listing the required fees.


Application No.: 10/522,150

Docket No.: 2815-0297PUS1

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated: **OCT 29 2007**

Respectfully submitted,

By 
Mary Anne Armstrong, Ph.D.
Registration No.: 40,069
BIRCH, STEWART, KOLASCH & BIRCH, LLP
8110 Gatehouse Road
Suite 100 East
P.O. Box 747
Falls Church, Virginia 22040-0747
(703) 205-8000
Attorney for Applicant